Financial Performance - Net revenue for Q2 2025 reached $214 million, a 13.9% increase year-over-year[10] - Adjusted EBITDA for Q2 2025 was $25 million, representing an 11.7% margin[10] - The company projects full year 2025 net revenue to be between $880 million and $888 million, representing approximately 14-15% year-over-year growth[28] - The company anticipates full year 2025 Adjusted EBITDA to be between $98 million and $101 million, with an 11.1-11.4% margin[28] - For Q3 2025, the company expects net revenue between $223 million and $225 million, a growth of approximately 16-17% year-over-year, with an Adjusted EBITDA margin of approximately 11%[30] Business Highlights - The company has 298 stores, including 293 in the U S and 5 in Canada[8, 23] - The company estimates a potential footprint of over 900 stores[24] - Over 20 million pairs of glasses have been distributed through the Buy a Pair, Give a Pair program[8] Customer Retention - The company demonstrates compelling and consistent sales retention rates, with customer cohorts showing increasing sales retention over time[17]

Financial Performance & Guidance - Worldwide ARIKAYCE revenue reached $107.4 million, an increase of 18.9%[43] - U.S. ARIKAYCE revenue was $68.7 million, up 7.7%[43] - Japan ARIKAYCE revenue was $30.7 million, a significant increase of 45.3%[43] - Europe & Rest of World ARIKAYCE revenue grew by 48.3% to $8.1 million[43] - The company is on track to achieve its 2025 ARIKAYCE revenue guidance of $405 to $425 million[44] - The company holds a strong capital position with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of June 30, 2025[46] Clinical Development & Pipeline - All three late-stage assets (ARIKAYCE, brensocatib, and TPIP) have demonstrated clinical success[15] - Brensocatib is expected to launch in the U.S. in Q3 2025 for NCFB, pending regulatory approval[16] - Phase 2 BiRCh data for brensocatib in CRSsNP is expected by the end of 2025[16] - A futility analysis for the Phase 2 CEDAR trial of brensocatib in HS is anticipated in Q1 2026[16] - The Phase 2b study of TPIP in PAH exceeded expectations, showing a 35% reduction in PVR and a 35.5m improvement in 6MWD[39] - Phase 3 trial in PH-ILD is expected to initiate in 2H:25 and Phase 3 trial in PAH is expected to initiate in early 2026[16]

Financial Performance - The company's APE sales increased by 15% from C$19 billion to C$22 billion[17, 52] - New business CSM grew significantly by 37% from C$628 million to C$882 million[17, 52] - New business value increased by 20% from C$691 million to C$846 million[17, 52] - Core EPS increased by 2% from C$091 to C$095, while EPS increased significantly by 88%[19, 28] - Adjusted book value per share increased by 7%[20, 43] Business Segment Performance - Asia's APE sales increased by 31% from US$920 million to US$1233 billion[31] - Asia's new business value increased by 28% from US$346 million to US$451 million[31] - Asia's new business CSM increased by 34% from US$349 million to US$480 million[31] - Global WAM net flows increased by C$08 billion from C$01 billion to C$09 billion[17, 25]

Q2 2025 Financial Performance - Adjusted net sales decreased by 4% from $464 million in Q2 2024 to $446 million in Q2 2025[75] - Coolers & Equipment adjusted net sales decreased by 3% from $206 million to $201 million[77] - Drinkware adjusted net sales decreased by 4% from $247 million to $236 million[79] - Wholesale adjusted net sales decreased by 7% from $213 million to $197 million, while Direct-to-Consumer adjusted net sales decreased by 1% from $250 million to $249 million[81] - Adjusted gross profit decreased by 4% from $268 million to $258 million, with an adjusted gross margin increase of 10 bps from 57.7% to 57.8%[83] - Adjusted operating income decreased by 9% from $80 million to $73 million, with an adjusted operating margin decrease from 17.3% to 16.4%[85] - Adjusted SG&A expenses decreased by 2% from $188 million to $184 million, with an adjusted SG&A as a percentage of adjusted net sales increase from 40.5% to 41.3%[87] - Adjusted EPS decreased by 6% from $0.70 to $0.66, including a $0.07 per share impact from higher net tariff costs[88] Strategic Highlights - Expanded customer base through a strategic partnership with Fanatics, enhancing presence in sports licensing with custom NFL, MLB, NHL, and NCAA offerings[9] - Launched the all-weather Cayo backpack in late Q2 2025, exceeding initial expectations[9] - DTC sales decreased 1% YoY during Q2 2025, with growth in Amazon and Corporate Sales offset by softer US Ecomm demand[10] - Wholesale launch in Japan in late Q2 expanded distribution from 17 to over 270 doors and established a digital presence[10] FY 2025 Outlook (as of 8/7/25) - Adjusted Net Sales: Flat to Up 2% YoY[109] - Adjusted Operating Margin: 14.0% to 14.5%[109] - Adjusted Income per Diluted Share: ~$2.34 to $2.48, Down ~14% to 9% YoY[109] - Capital Expenditures: ~$50M[109] - Free Cash Flow: ~$150M to $200M[109]

Financial Performance & Profitability - Total revenues for 2Q'25 reached $110.0 million, a 9% increase year-over-year[56] - Adjusted loss from operations improved by 37% year-over-year, from $(54.485) million in 2Q'24 to $(34.187) million in 2Q'25[10, 86] - The company is on track to achieve profitability in 4Q'25, referring to adjusted income from operations[10, 18] - Cash position remains strong at $832.3 million as of June 30, 2025[10] Key Products & Pipeline Updates - VYVGART/VYVGART Hytrulo sales grew 14% year-over-year, reaching $26.5 million in 2Q'25, driven by increased market penetration and extension of DoT[56, 59] - ZL-1310 (DLL3 ADC) showed a 67% ORR in 2L SCLC across all doses and 79% ORR with 1.6 mg/kg (n=14)[42] - Bemarituzumab met the primary endpoint of overall survival in the global Ph3 FORTITUDE-101 study[10, 32] - KarXT's China NDA was accepted in January 2025, showing early and sustained reduction of positive and negative symptoms[26] Strategic Focus & Future Outlook - The company aims to unlock the blockbuster potential of VYVGART and VYVGART Hytrulo through execution excellence, targeting increased HCP coverage and supplemental insurance coverage[19, 20] - Multiple revenue inflections are expected through 2030, with an expected $2 billion revenue in 2028[18] - Zai Lab plans to initiate a global pivotal study of ZL-1310 in 2L ES-SCLC in 2H'25[15, 40]

Financial Performance Highlights - Total revenue for FY25 reached $1.14 billion[9], a sequential growth led by APAC and EMEA regions[7] - Non-GAAP Gross Profit for FY25 was $717 million[9], resulting in a Non-GAAP Gross Margin of 62.9%[9] - Non-GAAP Operating Margin for FY25 was 14.2%[9], with Non-GAAP EBITDA reaching $175 million[9] - Non-GAAP EPS for FY25 was $0.84[9] - The company's cash position grew to $232 million[7], with net cash reaching $52 million[7, 9] Recurring Revenue and SaaS Growth - Recurring revenue reached $109 million in 4Q25, up 8% sequentially and year-over-year[7] - SaaS ARR reached $208 million, up 24% year-over-year[7, 9] - Total deferred recurring revenue reached $606 million, up 9% year-over-year[7] - Recurring revenue accounted for 36% of total revenue[9] Bookings and Customer Acquisition - The company repurchased 1.5 million shares for $25 million[7] - The company acquired 168 large customers with over $1 million in bookings during the fiscal year[9] - Government and Education sectors contributed approximately 40% of the total bookings[12] Q1 2026 (1Q26) Financial Guidance - The company projects revenue between $292 million and $300 million[53] - The company projects Non-GAAP gross margin between 61.9% and 62.3%[53] - The company projects Non-GAAP operating margin between 12.7% and 14.5%[53] - The company projects Non-GAAP EPS between $0.20 and $0.23[53]

FY25 Performance Highlights - CACI achieved 16% underlying revenue growth, with 10% being organic[12] - The company secured $10 billion in contract awards, representing a 1.1x TTM book-to-bill ratio[12] - CACI reported an EBITDA margin of 11.2%[12,26] - Free cash flow reached $442 million, demonstrating efficient management of working capital and capital expenditures[12,26] - Adjusted EPS increased by 26% year-over-year[26] FY26 Guidance - CACI anticipates revenue growth of nearly 8% at the midpoint, with a range of 6.6% to 8.9%[22] - The company expects an EBITDA margin in the "mid 11% range"[22] - Free cash flow and free cash flow per share are projected to grow by more than 60%[22] - CACI forecasts free cash flow of at least $710 million[33] Capital Deployment and Balance Sheet - CACI repurchased 436,000 shares at an average price of $344 per share[12,32] - The company closed a $1 billion upsized offering of 6.375% senior unsecured notes[32] - CACI has a strong balance sheet with 2.9x leverage[32]

Financial Performance & Guidance - Q2 2025 revenue reached $214.8 million [4] - Q2 2025 gross margin exceeded guidance at 31.2% [4] - Q2 2025 EPS was 9.5 cents, within the guidance of 8.5 to 11.5 cents [5] - Q3 2025 revenue is expected to decrease by 12% to 17% QoQ [28] - Q3 2025 net loss is projected to be 2.0 cents to 4.0 cents per diluted ADS [28] Segment Performance - SMDDIC (Small & Medium Display Driver IC) revenue in Q2 2025 was $144.5 million [7], a decrease of 4.0% QoQ [11] - LDDIC (Large Display Driver IC) revenue in Q2 2025 was $24.9 million [7], a decrease of 0.6% QoQ [10] - Non-Driver revenue in Q2 2025 was $45.4 million [7], an increase of 14.7% QoQ [16] Business Outlook & Strategy - The company maintains a conservative outlook for Q3 and is controlling expenses while reducing procurement costs [30] - The company is accelerating geographic diversification of foundry & backend to address customer needs [30] - The company holds the No 1 global market share across all segments of auto display ICs [31]

Q3 FY25 Financial Performance - Adjusted revenue increased by 8.9% to $5.509 billion, with organic revenue growth of 3.0%[37] - Adjusted diluted EPS grew by 5.1% year-over-year to $3.68[26, 37] - Adjusted operating margin increased by 60 bps year-over-year to 25.8%[26] - Free cash flow decreased by 25% year-over-year to $1.667 billion YTD, impacted by increased inventory and tariff payments[39] Segment Performance - BD Medical revenue increased by 14.0% FXN to $2.927 billion, with 3.2% organic growth[26, 28] - BD Life Sciences revenue decreased by 1.1% FXN to $1.254 billion[26, 31] - BD Interventional revenue increased by 6.8% FXN to $1.328 billion[26, 33] FY25 Guidance - The company reaffirmed organic revenue growth guidance of 3.0% to 3.5%[17, 41] - Adjusted diluted EPS guidance increased to $14.30 to $14.45, reflecting 9.4% year-over-year growth at the midpoint[17, 41] - Estimated total company revenue is projected to be approximately $21.8 billion to $21.9 billion[41]

Product & Technology - D-Wave announced the general availability of its Advantage2 quantum computer, featuring a more advanced quantum processor with increased connectivity, reduced noise, and greater coherence[6] - D-Wave is developing advanced cryogenic packaging, leveraging expertise from NASA JPL, aiming for a 100,000 qubit Advantage3 system[8] - D-Wave released new quantum AI/ML developer tools, including an open-source toolkit, to integrate quantum computers into modern ML architectures[11] Customer & Partnerships - D-Wave has a strong customer base and is a market leader in quantum annealing[5] - D-Wave is engaged in exciting customer engagements for both commercial and research applications, including EON, GE Vernova, Nikon Corporation, NTT Data Corp, NTT DOCOMO, Sharp Corporation, and The University of Oxford[16, 17] - D-Wave established a strategic relationship with Yonsei University and Incheon Metropolitan City to promote quantum computing in South Korea, including a potential Advantage2 system acquisition[13, 14] Financials - D-Wave completed a $400 million At-the-Market equity offering[19] - D-Wave's cash balance as of June 30, 2025, was approximately $8193 million[20] - D-Wave's Q2 2025 revenue was $22 million, with a gross profit of $20 million[23] - D-Wave's 1H 2025 revenue was $181 million, with a gross profit of $159 million and a gross margin of 876%[24, 26]